Dalriada Therapeutics
Business Services · Canada · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2820 Argentia Road Units 8-9, Mississaug...Phone Number
(647) 869-7948Website
www.dalriadatx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
2
1
1
About Dalriada Therapeutics
Dalriada Drug Discovery specializes in turn-key drug discovery services, leveraging over 300 years of combined experience in pharma and biotech, with a team comprising more than 70% Ph.D. scientists. They offer a comprehensive range of services from target validation to lead optimization across various therapeutic areas, including cannabinoid and psychedelic programs. Their state-of-the-art facilities and innovative approach facilitate rapid, data-driven discovery cycles, ensuring seamless collaboration and execution for their clients. Dalriada aims to partner with organizations seeking to advance their drug discovery efforts, providing tailored solutions to meet complex challenges in the development of new therapies.Explore more
Dalriada Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dalriada Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Dalriada Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Dalriada Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Dalriada Therapeutics
Product Launch: Get notified when Dalriada Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Dalriada Therapeutics recently announced quarterly report
Dalriada Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Dalriada Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Dalriada Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined Dalriada Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Dalriada Therapeutics
Compare insights from companies similar to Dalriada Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Dalriada Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Dalriada Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Dalriada Therapeutics.
Dalriada Therapeutics Tech Stack
A closer look at the technologies used by Dalriada Therapeutics
See more technologies
Dalriada Therapeutics News & Media
Dalriada brings in former Evotec executive Adam Davenport to lead strategy execution as Chief R&D Officer
TORONTO, May 03, 2023 (GLOBE NEWSWIRE) -- Dalriada, a leading Canadian contract research organization specializing in small molecule therapies, announces today that it has strengthened its executive leadership team, appointing Adam Davenport, Ph.D. as its Chief Research & Development Officer (CRDO).Dalriada Drug Discovery to Collaborate with atai Life Sciences' New Platform Company to Discover Next-Generation Therapies for Mental Health
TORONTO, Jan. 27, 2022 /PRNewswire/ -- Dalriada Drug Discovery ("Dalriada") is pleased to announce a strategic collaboration with atai Life Sciences' N.V. (Nasdaq: ATAI) newly launched platform company Invyxis, focused on developing next-generation small molecule therapies based on...Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE IP Portfolio
VANCOUVER, British Columbia, June 08, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, is pleased to announce it has selected Toronto-based Dalriada Drug Discovery Inc. (“Dalriada”) to advance its new chemical entity (“NCE”) IP portfolio as it pertains to ketamine and psilocybin/psilicin molecular scaffolds.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Dalriada Therapeutics
Sign Up For FreeTo access detailed company insights
Dalriada Drug Discovery specializes in turn-key drug discovery services, leveraging over 300 years of combined experience in pharma and biotech, with a team comprising more than 70% Ph.D. scientists. They offer a comprehensive range of services from target validation to lead optimization across various therapeutic areas, including cannabinoid and p... Read More
